Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Leukemia · 2026 · PMC12789019 · PMID 41184633

Europe PMC DOI

hedged sentence

0.2500

closest p · 5.0× alpha

0.2500

boldest claim

The sentences

showed a trendp = 0.25not close (p > 0.1)

cfDNA high (>4.19 log 10 hGE/mL) significantly predicted OS rates ( p = 0.043, HR:3.42[0.96–12.15]) and showed a trend towards inferior FFS ( p = 0.25, HR:1.82[0.65–5.05]) (Fig. 2B, C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.